Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics for serious viral diseases, and its news flow reflects this development-driven profile. Company announcements frequently center on progress in its hepatitis C virus (HCV) program, where Atea is advancing a fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and ruzasvir, an NS5A inhibitor.
News items include updates on the global Phase 3 HCV program, such as enrollment milestones in the C-BEYOND and C-FORWARD trials, expectations for topline results, and details of trial design, endpoints and patient populations. Atea also reports new clinical and nonclinical data, including Phase 2 efficacy results, resistance analyses, pharmacokinetic findings and multiscale modeling that explore the regimen’s antiviral activity, barrier to resistance, relative bioavailability and dosing flexibility.
Investors and observers can also find press releases about Atea’s participation in major medical and investor conferences, including presentations at The Liver Meeting of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Congress, as well as appearances at healthcare investment conferences. These communications often highlight new data sets, key opinion leader events and discussions of the HCV commercial landscape.
In addition, Atea’s news coverage includes pipeline expansion updates, notably the development of nucleotide analog candidates AT-587 and AT-2490 for hepatitis E virus (HEV), along with background on the unmet medical need in HEV and the company’s preclinical findings. Financial results releases and business updates, furnished in connection with quarterly reports, provide further context on research and development spending, cash resources and strategic priorities. For those tracking AVIR, this news page offers a centralized view of clinical progress, scientific presentations, pipeline evolution and corporate developments.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced promising results from three Phase 1 studies of bemnifosbuvir presented at the CROI conference (Feb 19-22, 2023). The data indicates that bemnifosbuvir has a favorable drug-drug interaction profile, requiring no dosage adjustments when co-administered with CYP3A substrates and other commonly prescribed medications for patients at risk of severe COVID-19. This investigational antiviral is currently being evaluated in the Phase 3 SUNRISE-3 trial targeting high-risk non-hospitalized COVID-19 patients. The findings highlight bemnifosbuvir's potential to safely enhance treatment options for vulnerable populations.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced a live conference call scheduled for February 28, 2023, at 4:30 p.m. ET. The call will disclose financial results for the fourth quarter and full year ended December 31, 2022, alongside a business update. Atea focuses on developing oral therapies for serious viral diseases, including COVID-19 and hepatitis C, utilizing its proprietary nucleos(t)ide prodrug platform. The event will be accessible via registration, with a live webcast available on the Atea website. Archived content will be accessible for 90 days post-event.
BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced two poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) taking place from February 19-22, 2023, in Seattle. The posters include:
- Poster 512: No Dose Adjustments for CYP3A4 Substrates with Bemnifosbuvir
- Poster 513: Bemnifosbuvir Has Low Potential to Inhibit P-gp, BCRP, and OATP1B1 Mediated Transport
Atea focuses on developing oral therapies for severe viral diseases and utilizes a proprietary nucleos(t)ide prodrug platform to create candidates targeting ssRNA viruses like COVID-19, dengue, and hepatitis C.
BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that its CEO, Jean-Pierre Sommadossi, will present a business update during a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 3:00 p.m. ET. A live webcast of the event will be accessible here and will remain available for 90 days after the event.
Atea specializes in developing oral therapies for severe viral diseases, focusing on antiviral treatments for COVID-19, dengue, and HCV.
Atea Pharmaceuticals (Nasdaq: AVIR) provided a clinical update, highlighting progress in its pipeline for 2023. The SUNRISE-3 Phase 3 trial for bemnifosbuvir, targeting high-risk, non-hospitalized COVID-19 patients, continues with interim analysis expected in 2H23. The company anticipates proof-of-concept results for AT-752 for dengue in 1Q23, and initiation of a Phase 2 study of bemnifosbuvir and ruzasvir for Hepatitis C in 2Q23, with data expected in 4Q23. Atea boasts a strong balance sheet to support these initiatives through 2025.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a business update at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:00 p.m. PT in San Francisco. A live webcast of the presentation will be available on Atea's website and will remain accessible for 90 days. Atea, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for severe viral diseases, including COVID-19, dengue, and hepatitis C.
Atea Pharmaceuticals (AVIR) has initiated the SUNRISE-3 Phase 3 trial to evaluate bemnifosbuvir, an oral antiviral treatment for COVID-19, in high-risk non-hospitalized patients. The trial aims to enroll at least 1,500 participants and will assess its efficacy against hospitalization and death. Bemnifosbuvir targets the SARS-CoV-2 RNA polymerase, boasting a unique mechanism that helps mitigate resistance. Previous late-stage trials indicated a 71% reduction in hospitalization rates for treated patients compared to placebo. This development highlights Atea's focus on unmet medical needs in COVID-19 treatment.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi and the management team will present a business update at the 5th Annual Evercore ISI HealthCONx Conference on November 29 at 9:40 a.m. ET. A live webcast will be available on the company’s website, with an archived version accessible for 90 days post-event.
Atea focuses on developing oral antiviral therapies for severe diseases, including COVID-19, hepatitis C, and dengue, leveraging its nucleos(t)ide prodrug platform to address unmet medical needs.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a business update at the Jefferies London Healthcare Conference on November 15, 2022, at 5:00 p.m. GMT / 12:00 p.m. ET. The event will be accessible via a live webcast and archived for 90 days post-event. Atea focuses on developing oral therapies for severe viral infections, leveraging its nucleos(t)ide prodrug platform. Current efforts include targeting COVID-19, hepatitis C, and other severe viral diseases.
Atea Pharmaceuticals (Nasdaq: AVIR) announced key updates and financial results for Q3 2022, reporting a net loss of $8.1 million, down from a loss of $28.2 million in 2021. The company holds $665 million in cash and marketable securities. Notably, the SUNRISE-3 trial for bemnifosbuvir in high-risk COVID-19 patients is set to enroll before year-end 2022. Additionally, Atea plans to submit trial applications for a hepatitis C combination study. Research and development expenses decreased significantly, attributed to the termination of a cost-sharing agreement with Roche.